DOTmed May 23, 2024
Lunit, a leader in AI-powered cancer diagnostics and therapeutics, has finalized its acquisition of Volpara Health Technologies, a global provider of medical software for breast cancer screening, for $193 million. This acquisition significantly enhances Lunit’s capabilities in AI-driven cancer diagnostics.
The integration of Volpara’s advanced breast health platform, including technologies for breast density assessment and screening workflow enhancement, with Lunit’s AI solutions creates a comprehensive suite for breast cancer diagnostics. The combined offering is poised to streamline administrative processes, positioning the company as a leader in the industry.
Volpara’s presence in over 2,000 U.S. medical sites provides Lunit with a strategic entry into the American market, the largest healthcare market globally. Additionally, the recent recommendation by the US Preventive Services...
Today's Sponsors
Today's Sponsor